Mycophenolic Acid Exposure after Administration of Mycophenolate Mofetil in the Presence and Absence of Ciclosporin in Renal Transplant Recipients

被引:43
|
作者
Kuypers, Dirk R. [1 ]
Ekberg, Henrik [2 ]
Grinyo, Josep [3 ]
Nashan, Bjoern [4 ]
Vincenti, Flavio [5 ]
Snell, Paul [6 ]
Mamelok, Richard D. [7 ]
Bouw, Rene M. [6 ]
机构
[1] Univ Hosp Leuven, Dept Nephrol, Louvain, Belgium
[2] Lund Univ, Dept Transplantat, Malmo, Sweden
[3] Bellvitge Hosp, Dept Nephrol, Barcelona, Spain
[4] Univ Med Ctr Hamburg Eppendorf, Dept Hepatobiliary Surg & Visceral Transplantat, Hamburg, Germany
[5] Univ Calif San Francisco, Dept Kidney Transplantat, San Francisco, CA 94143 USA
[6] Roche Prod Ltd, Dept Clin Pharmacol, Welwyn Garden City AL7 3AY, Herts, England
[7] Mamelok Consulting, Palo Alto, CA USA
关键词
RESISTANCE-ASSOCIATED PROTEIN-2; ACUTE REJECTION; KIDNEY-TRANSPLANTATION; ALLOGRAFT RECIPIENTS; DRUG EXPOSURE; PHARMACOKINETICS; PREVENTION; GLUCURONIDE; WITHDRAWAL; TRIAL;
D O I
10.2165/00003088-200948050-00005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and objective: The pharmacokinetics of mycophenolic acid (MPA) are complex, with large interindividual variability over time. There are also well documented interactions with ciclosporin, and assessment of MPA exposure is therefore necessary when reducing or stopping ciclosporin therapy. Here we report on the pharmacokinetic and pharmacodynamic behaviour of MPA in renal transplant patients on standard dose, reduced dose and no ciclosporin. Study design: The CAESAR study, a prospective 12-month study in primary renal allograft recipients, was designed to determine whether mycophenolate mofetil-based regimens containing either low-dose ciclosporin or low-dose ciclosporin withdrawn by 6 months could minimize nephrotoxicity and improve renal function without an increase in acute rejection compared with a mycophenolate mofetil-based regimen containing standard-dose ciclosporin. Patients and methods: A subset of patients from the CAESAR study contributed to this pharmacokinetic analysis of MPA exposure. Blood samples were taken over one dosing interval on day 7 and at months 3, 7 and 12 post-transplantation. The sampling timepoints were predose, 20, 40 and 75 minutes and 2, 3, 4, 6, 9 and 12 hours after mycophenolate mofetil dosing. Assessments included plasma concentrations of MPA and mycophenolic acid glucuronide (MPAG) and ciclosporin trough concentrations. The area under the plasma concentration-time curve (AUC) from 0 to 12 hours (AUC(12)) for MPA was the primary pharmacokinetic parameter, and the AUC12 for MPAG was the secondary parameter. Results: In total, 536 de novo renal allograft recipients were randomized in the CAESAR study. Of these, 114 patients were entered into the pharmacokinetic substudy and 110 patients contributed to the pharmacokinetic analysis. There was a rapid rise in MPA concentrations (median time to peak concentration 0.72-1.25 hours). At day 7 and month 3, the MPA AUC12 values were similar in the ciclosporin withdrawal and low-dose ciclosporin groups (patients with the same ciclosporin target concentrations to month 6), while at 7 and 12 months, the values in the ciclosporin withdrawal group were higher than in the low-dose group (19.9% and 30.2% higher, respectively). MPA AUC12 values in the standard-dose ciclosporin group were lower than in the other groups at all timepoints and increased over time. At all timepoints, the MPA peak plasma concentration was similar in all groups, and the MPAG concentrations rose more slowly than MPA concentrations. The ratio of the AUC from 6 to 12 hours/AUC(12) suggests that an increasing AUC in the ciclosporin withdrawal group is due to an increase in the enterohepatic recirculation. Conclusion: These findings are consistent with the hypothesis that ciclosporin inhibits the biliary secretion and/or hepatic extraction of MPAG, leading to a reduced rate of enterohepatic recirculation of MPA. Several concurrent mechanisms, such as ciclosporin-induced changes in renal tubular MPAG excretion and enhanced elimination of free MPA through competitive albumin binding with MPAG, can also contribute to the altered MPAG pharmacokinetics observed in the presence and absence of ciclosporin.
引用
收藏
页码:329 / 341
页数:13
相关论文
共 50 条
  • [31] POPULATION PHARMACOKINETIC-PHARMACODYNAMIC MODEL OF MYCOPHENOLIC ACID WITH INOSINE MONOPHOSPHATE DEHYDROGENASE ACTIVITY FOLLOWING ADMINISTRATION OF MYCOPHENOLATE MOFETIL IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS.
    Fukuda, T.
    Dong, M.
    de Vries, M. T.
    Cox, S.
    Goebel, J.
    Vinks, A. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S127 - S127
  • [32] Population Pharmacokinetics of Mycophenolic AcidA Comparison between Enteric-Coated Mycophenolate Sodium and Mycophenolate Mofetil in Renal Transplant Recipients
    Brenda C. M. de Winter
    Teun van Gelder
    Petra Glander
    Dario Cattaneo
    Helio Tedesco-Silva
    Irmgard Neumann
    Luuk Hilbrands
    Reinier M. van Hest
    Mark D. Pescovitz
    Klemens Budde
    Ron A. A. Mathot
    Clinical Pharmacokinetics, 2008, 47 : 827 - 838
  • [33] Minimizing ciclosporin in renal transplant recipients on daclizumab, mycophenolate and steroids
    Bunnapradist, Suphamai
    Danovitch, Gabriel M.
    NATURE CLINICAL PRACTICE NEPHROLOGY, 2007, 3 (08): : 426 - 427
  • [34] Minimizing ciclosporin in renal transplant recipients on daclizumab, mycophenolate and steroids
    Suphamai Bunnapradist
    Gabriel M Danovitch
    Nature Clinical Practice Nephrology, 2007, 3 : 426 - 427
  • [35] Elective withdrawal of mycophenolate mofetil in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone
    ter Meulen, CG
    Gregoor, PJHS
    Weimar, W
    Hilbrands, LB
    TRANSPLANT INTERNATIONAL, 2001, 14 (02) : 99 - 102
  • [36] Population Pharmacokinetics and Pharmacogenetics of Mycophenolic Acid Following Administration of Mycophenolate Mofetil in De Novo Pediatric Renal-Transplant Patients
    Zhao, Wei
    Fakhoury, May
    Deschenes, Georges
    Roussey, Gwenaelle
    Brochard, Karine
    Niaudet, Patrick
    Tsimaratos, Michel
    Andre, Jean Luc
    Cloarec, Sylvie
    Cochat, Pierre
    Bensman, Albert
    Azougagh, Said
    Jacqz-Aigrain, Evelyne
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (11): : 1280 - 1291
  • [37] Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study
    Saliba, Faouzi
    Rostaing, Lionel
    Gugenheim, Jean
    Durand, Francois
    Radenne, Sylvie
    Leroy, Vincent
    Neau-Cransac, Martine
    Calmus, Yvon
    Salame, Ephrem
    Pageaux, Georges-Philippe
    Duvoux, Christophe
    Taguieva, Naila
    Sinnasse-Raymond, Gilles
    Sebagh, Mylene
    Samuel, Didier
    Marquet, Pierre
    TRANSPLANTATION, 2016, 100 (08) : 1705 - 1713
  • [38] Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy
    Weber, LT
    Shipkova, M
    Armstrong, VW
    Wagner, N
    Schütz, E
    Mehls, O
    Zimmerhackl, LB
    Oellerich, M
    Tönshoff, B
    CLINICAL CHEMISTRY, 2002, 48 (03) : 517 - 525
  • [39] High mycophenolic acid area under-the-curve values in renal transplant recipients on long-term mycophenolate mofetil treatment
    Engelbertink, R
    Gregoor, PS
    Hesse, C
    IJzermans, J
    Weimar, W
    van Gelder, T
    TRANSPLANTATION PROCEEDINGS, 2002, 34 (07) : 2983 - 2984
  • [40] Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil
    Tedesco-Silva, H
    Bastien, MC
    Choi, L
    Felipe, C
    Campestrini, J
    Picard, F
    Schmouder, R
    TRANSPLANTATION PROCEEDINGS, 2005, 37 (02) : 852 - 855